Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Minimum effective induction dose of esketamine in opioid-free general anesthesia for modified radical mastectomy
ChiCTR2400086503Phase 4Not yet recruiting
- Sponsor
- The 2nd Affiliated Hospital of Chongqing Medical University
- Start
- Jul 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of esketamine in breast cancer, sponsored by The 2nd Affiliated Hospital of Chongqing Medical University. Primary endpoints: Heart rate, Mean arterial pressure and 4 more. Planned start Jul 2024; status: not yet recruiting.
02
Drugs
esketamine
03
Conditions
breast cancer
Beyond the preview
Go deeper on ChiCTR2400086503.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400086503.